Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Earnings for Enanta Pharmaceuticals, Inc. (ENTA)
Earnings in 2024 (TTM): $-117,788,000
According to Enanta Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-117,788,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Enanta Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-117,788,000 | $-116,045,000 |
| 2023 | $-130,995,000 | $-133,816,000 |
| 2022 | $-122,188,000 | $-121,755,000 |
| 2021 | $-107,579,000 | $-78,996,000 |
| 2020 | $-35,019,000 | $-36,168,000 |
| 2019 | $45.56 M | $46.38 M |
| 2018 | $93.12 M | $71.96 M |
| 2017 | $26.95 M | $17.71 M |
| 2016 | $32.56 M | $21.67 M |
| 2015 | $125.46 M | $78.99 M |
| 2014 | $19.27 M | $34.44 M |
| 2013 | $9.63 M | $9.63 M |
| 2012 | $21.4 M | $21.4 M |
| 2011 | $23.31 M | $23.31 M |
| 2010 | $7.75 M | $7.9 M |